相关实验视频
Updated: Jun 11, 2025

15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
9.6K
了解肌缩侧面硬化症:病理生理学,诊断和治疗进展
Radu Eugen Rizea1,2, Antonio-Daniel Corlatescu1, Horia Petre Costin1
1Department of Neurosurgery, University of Medicine and Pharmacy, "Carol Davila", 020021 Bucharest, Romania.
International journal of molecular sciences
|September 28, 2024
概括
这篇评论探讨了肌缩性侧面硬化症 (ALS),详细介绍了其原因,诊断和治疗方法. 研究强调了遗传和环境因素,分子机制,以及有前途的新疗法,如对ALS的基因和干细胞治疗.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种复杂的神经退行性疾病,具有显著的遗传和环境影响.
- 了解分子基础,包括蛋白质错折和氧化应激,对于治疗的发展至关重要.
研究的目的:
- 提供ALS的全面审查,涵盖流行病学,病理生理学,诊断和治疗.
- 综合了最近的分子机制和ALS治疗策略的进展.
主要方法:
- 关于ALS的流行病学,病理生理学和临床数据的文献综述.
- 对分子机制 (如蛋白质错折,线粒体功能障碍) 和治疗点的研究分析.
- 评估当前和新兴的治疗方法,包括基因和干细胞疗法.
主要成果:
- 精细的诊断标准和生物标志物使得早期和更准确的ALS诊断成为可能.
- 确定了关键的分子机制,提供了潜在的治疗点.
- 像基因和干细胞治疗这样的新兴疗法显示出改变ALS进展的希望.
结论:
- 尽管取得了进展,但目前的ALS治疗提供了有限的益处,需要新的治疗方法.
- 对分子机制和先进疗法的持续研究对于改善ALS患者的治疗结果至关重要.
- 临床实践必须适应整合新的治疗方法和支持ALS护理研究.
相关概念视频
Parkinson's Disease: Overview
492
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
492
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Parkinson's Disease: Treatment
233
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
233

